Schwarzach Im Pongau

Researchers are conducting the Austrian Hypertrophic Cardiomyopathy HCM Registry, a prospective study enrolling patients from multiple outpatient clinics across Austria, including academic and non-academic centers. The registry aims to collect detailed clinical data on patients with HCM to facilitate innovative epidemiological analyses and improve standards of care by understanding gaps in evidence for this heart condition. Participants undergo a structured examination process that includes assessment of HCM symptoms, medical and family history, medication use, and specific red flags related to HCM. Clinical data collected include electrocardiograms, echocardiography, laboratory tests, and genetic testing. All information is entered into an electronic case report form to support multicenter analyses approved by a steering committee. During the study, patients will be followed over an average of 20 years with ongoing collection of data related to all-cause mortality and cardiovascular events. The registry supports cross-sectional and longitudinal analyses, aiming to harmonize clinical care for HCM patients in Austria. The total participation time depends on continued follow-up and data collection throughout the study duration.

Researchers are evaluating whether a faster hospital discharge after invasive treatment for acute myocardial infarction heart attack is as safe as the standard longer stay. This trial compares a fast discharge strategy, where patients leave the hospital about 24 hours after treatment, to the usual care of staying more than 36 hours. The study aims to find out if early discharge increases the risk of major heart-related problems over a year following the heart attack. Participants are randomly assigned to one of two groups one group receives standard care with discharge after more than 36 hours, while the other group is discharged early at around 24 hours following invasive management. This approach includes patients who had successful procedures to open blocked heart arteries. The trial is conducted at multiple centers and monitors patients for up to 12 months after randomization. During the study, participants will be regularly assessed for major adverse cardiovascular events such as heart attacks, strokes, hospital readmissions, bleeding events, and death from any cause. Researchers will also measure hospital stay length, healthcare costs, and treatment adherence. Follow-up includes monitoring these outcomes up to 12 months after the initial treatment to evaluate the safety and impact of the faster discharge plan.

Researchers are investigating the effect of high-dose vitamin D3 on mortality in adult critically ill patients, particularly those with severe vitamin D deficiency. Previous studies found no benefit in hospital length of stay but suggested a significant reduction in 28-day mortality in patients with very low vitamin D levels. This phase III randomized controlled trial aims to confirm these findings in a larger, multicenter setting. Participants will be randomly assigned to receive either a high dose of vitamin D3 or a placebo. The vitamin D3 group will get an oral loading dose of 540,000 IU dissolved in 37.5 ml of medium chain triglycerides MCT, followed by 4000 IU daily 10 drops for 90 days. The placebo group will receive an identical MCT loading dose and daily drops for the same duration. The study features a double-blind design and an interim analysis after half of the planned patients complete 28 days. During the study, participants will be monitored for 28-day mortality as the primary outcome. Secondary outcomes include hospital length of stay, hypercalcemia at day 5, and hospital readmissions within 90 days. The study involves regular assessments, safety monitoring by an independent board, and continued enrollment while interim analyses are conducted. Total participation spans at least 90 days with detailed follow-up.